Assessment of reported adverse events after substitution between TNF alfa inhibitors biosimilars in the WHO pharmacovigilance database

被引：0
|
作者：
Orhon, P. [1 ]
Robert, M. [1 ]
Bernardeau, C. [1 ]
Fusaroli, M. [2 ]
Roustit, M. [3 ]
Cracowski, J. L. [1 ]
Khouri, C. [1 ]
机构：
[1] Grenoble Alpes Univ Hosp, Pharmacovigilance Unit, Grenoble, France
[2] Dept Med & Surg Sci, Pharmacol Unit, Bologna, Italy
[3] Grenoble Alpes Univ Hosp, Clin Pharmacol Dept, Grenoble, France
来源：
FUNDAMENTAL & CLINICAL PHARMACOLOGY | 2023年 / 37卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PS-115
引用
收藏
页码：160 / 160
页数：1
相关论文
共 50 条
  • [1] Assessment of Reported Adverse Events After Interchanging Between TNF-α Inhibitor Biosimilars in the WHO Pharmacovigilance Database
    Pauline, Orhon
    Robert, Marion
    Bernardeau, Claire
    Hlavaty, Alex
    Fusaroli, Michele
    Roustit, Matthieu
    Cracowski, Jean-Luc
    Khouri, Charles
    BIODRUGS, 2023, 37 (05) : 699 - 707
  • [2] Assessment of Reported Adverse Events After Interchanging Between TNF-α Inhibitor Biosimilars in the WHO Pharmacovigilance Database
    Orhon Pauline
    Marion Robert
    Claire Bernardeau
    Alex Hlavaty
    Michele Fusaroli
    Matthieu Roustit
    Jean-Luc Cracowski
    Charles Khouri
    BioDrugs, 2023, 37 : 699 - 707
  • [3] Analysis of Hydroxychloroquine Adverse Events Reported in the WHO Pharmacovigilance Database
    Ahmed, Nehad J.
    Alshehri, Ahmed M.
    Almalki, Ziyad S.
    Alahmari, Abdullah K.
    LATIN AMERICAN JOURNAL OF PHARMACY, 2023, 42 (01): : 25 - 30
  • [4] Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database
    Hoisnard, Lea
    Maury, Sebastien
    Mahevas, Matthieu
    El Karoui, Khalil
    Roy, Lydia
    Cohen, Jose L.
    Amiot, Aurelien
    Claudepierre, Pascal
    Grimbert, Philippe
    Sbidian, Emilie
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB137 - AB137
  • [5] Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database
    Hoisnard, Lea
    Lebrun-Vignes, Benedicte
    Maury, Sebastien
    Mahevas, Matthieu
    El Karoui, Khalil
    Roy, Lydia
    Zarour, Anissa
    Michel, Marc
    Cohen, Jose L.
    Amiot, Aurelien
    Claudepierre, Pascal
    Wolkenstein, Pierre
    Grimbert, Philippe
    Sbidian, Emilie
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [6] Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database
    Hoisnard, L.
    Lebrun-Vignes, B.
    Maury, S.
    Mahevas, M.
    El Karoui, K.
    Roy, L.
    Zarour, A.
    Michel, M.
    Cohen, J. L.
    Amiot, A.
    Claudepierre, P.
    Wolkenstein, P.
    Grimbert, P.
    Sbidian, E.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2022, 36 : 165 - 165
  • [7] Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database
    Léa Hoisnard
    Bénédicte Lebrun-Vignes
    Sébastien Maury
    Matthieu Mahevas
    Khalil El Karoui
    Lydia Roy
    Anissa Zarour
    Marc Michel
    José L. Cohen
    Aurélien Amiot
    Pascal Claudepierre
    Pierre Wolkenstein
    Philippe Grimbert
    Emilie Sbidian
    Scientific Reports, 12
  • [8] Evaluation of adverse events related to musculoskeletal system reported for COVID-19 vaccines in VigiBase: A WHO pharmacovigilance database
    Kaur, Rimple Jeet
    Charan, Jaykaran
    BRITISH JOURNAL OF PHARMACOLOGY, 2023, 180 : 1176 - 1177
  • [9] Safety of Biologic Therapies for Severe Asthma: An Analysis of Adverse Reactions Reported in the WHO Pharmacovigilance Database
    Cutroneo, P. M.
    Arzenton, E.
    Furci, F.
    Bulzomi, M.
    Caminati, M.
    Senna, G.
    Moretti, U.
    Trifiro, G.
    DRUG SAFETY, 2022, 45 (10) : 1160 - 1161
  • [10] A pharmacovigilance study of the association between proton pump inhibitors and tumor adverse events based on the FDA adverse event reporting system database
    Zhang, Ya-Jun
    Duan, Dan-Dan
    Tian, Qian-Yu
    Wang, Cai-E.
    Wei, Shu-Xun
    FRONTIERS IN PHARMACOLOGY, 2024, 15
12345